Catherine Buettner1, Robert L Greenman2, Long H Ngo1, Jim S Wu3. 1. Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. 2. Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA; Department of Radiology, Boston University Medical Center, One Boston Medical Center Place, Boston, MA 02218, USA. 3. Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA.
Abstract
OBJECTIVES: Statins partially block the production of coenzyme Q10 (CoQ10), an essential component for mitochondrial function. Reduced skeletal muscle mitochondrial oxidative capacity has been proposed to be a cause of statin myalgia and can be measured using 31phosphorus magnetic resonance spectroscopy (31P-MRS). The purpose of this study is to assess the effect of CoQ10 oral supplementation on mitochondrial function in statin users using 31P-MRS. DESIGN/ SETTING: In this randomized, double-blind, placebo-controlled pilot study, 21 adults aged 47-73 were randomized to statin+placebo (n=9) or statin+CoQ10 (n=12). Phosphocreatine (PCr) recovery kinetics of calf muscles were assessed at baseline (off statin and CoQ10) and 4 weeks after randomization to either statin+CoQ10 or statin+placebo. RESULTS: Baseline and post-treatment PCr recovery kinetics were assessed for 19 participants. After 4 weeks of statin+ CoQ10 or statin+placebo, the overall relative percentage change (100*(baseline-follow up)/baseline) in PCr recovery time was -15.1% compared with baseline among all participants, (p-value=0.258). Participants randomized to statin+placebo (n=9) had a relative percentage change in PCr recovery time of -18.9%, compared to -7.7% among participants (n=10) receiving statin+CoQ10 (p-value=0.448). CONCLUSIONS: In this pilot study, there was no significant change in mitochondrial function in patients receiving 4 weeks ofstatin+CoQ10 oral therapy when compared to patients on statin+placebo.
RCT Entities:
OBJECTIVES: Statins partially block the production of coenzyme Q10 (CoQ10), an essential component for mitochondrial function. Reduced skeletal muscle mitochondrial oxidative capacity has been proposed to be a cause of statin myalgia and can be measured using 31phosphorus magnetic resonance spectroscopy (31P-MRS). The purpose of this study is to assess the effect of CoQ10 oral supplementation on mitochondrial function in statin users using 31P-MRS. DESIGN/ SETTING: In this randomized, double-blind, placebo-controlled pilot study, 21 adults aged 47-73 were randomized to statin+placebo (n=9) or statin+CoQ10 (n=12). Phosphocreatine (PCr) recovery kinetics of calf muscles were assessed at baseline (off statin and CoQ10) and 4 weeks after randomization to either statin+CoQ10 or statin+placebo. RESULTS: Baseline and post-treatment PCr recovery kinetics were assessed for 19 participants. After 4 weeks of statin+ CoQ10 or statin+placebo, the overall relative percentage change (100*(baseline-follow up)/baseline) in PCr recovery time was -15.1% compared with baseline among all participants, (p-value=0.258). Participants randomized to statin+placebo (n=9) had a relative percentage change in PCr recovery time of -18.9%, compared to -7.7% among participants (n=10) receiving statin+CoQ10 (p-value=0.448). CONCLUSIONS: In this pilot study, there was no significant change in mitochondrial function in patients receiving 4 weeks of statin+CoQ10 oral therapy when compared to patients on statin+placebo.
Authors: Catherine Buettner; Matthew J Rippberger; Julie K Smith; Suzanne G Leveille; Roger B Davis; Murray A Mittleman Journal: Am J Med Date: 2012-02 Impact factor: 4.965
Authors: Catherine R Mikus; Leryn J Boyle; Sarah J Borengasser; Douglas J Oberlin; Scott P Naples; Justin Fletcher; Grace M Meers; Meghan Ruebel; M Harold Laughlin; Kevin C Dellsperger; Paul J Fadel; John P Thyfault Journal: J Am Coll Cardiol Date: 2013-04-10 Impact factor: 24.094